Differential Modulation of Innate Immune Responses in Human Primary Cells by Influenza A Viruses Carrying Human or Avian Nonstructural Protein 1.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
12 12 2019
Historique:
received: 10 07 2019
accepted: 29 09 2019
pubmed: 11 10 2019
medline: 12 6 2020
entrez: 11 10 2019
Statut: epublish

Résumé

The influenza A virus (IAV) nonstructural protein 1 (NS1) contributes to disease pathogenesis through the inhibition of host innate immune responses. Dendritic cells (DCs) release interferons (IFNs) and proinflammatory cytokines and promote adaptive immunity upon viral infection. In order to characterize the strain-specific effects of IAV NS1 on human DC activation, we infected human DCs with a panel of recombinant viruses with the same backbone (A/Puerto Rico/08/1934) expressing different NS1 proteins from human and avian origin. We found that these viruses induced a clearly distinct phenotype in DCs. Specifically, viruses expressing NS1 from human IAV (either H1N1 or H3N2) induced higher levels of expression of type I (IFN-α and IFN-β) and type III (IFN-λ1 to IFNλ3) IFNs than viruses expressing avian IAV NS1 proteins (H5N1, H7N9, and H7N2), but the differences observed in the expression levels of proinflammatory cytokines like tumor necrosis factor alpha (TNF-α) or interleukin-6 (IL-6) were not significant. In addition, using imaging flow cytometry, we found that human and avian NS1 proteins segregate based on their subcellular trafficking dynamics, which might be associated with the different innate immune profile induced in DCs by viruses expressing those NS1 proteins. Innate immune responses induced by our panel of IAV recombinant viruses were also characterized in normal human bronchial epithelial cells, and the results were consistent with those in DCs. Altogether, our results reveal an increased ability of NS1 from avian viruses to antagonize innate immune responses in human primary cells compared to the ability of NS1 from human viruses, which could contribute to the severe disease induced by avian IAV in humans.

Identifiants

pubmed: 31597767
pii: JVI.00999-19
doi: 10.1128/JVI.00999-19
pmc: PMC6912104
pii:
doi:

Substances chimiques

IL6 protein, human 0
INS1 protein, influenza virus 0
Interferon-alpha 0
Interleukin-6 0
Tumor Necrosis Factor-alpha 0
Viral Nonstructural Proteins 0
Interferon-beta 77238-31-4
Interferon-gamma 82115-62-6

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIAID NIH HHS
ID : U19 AI117873
Pays : United States

Informations de copyright

Copyright © 2019 Monteagudo et al.

Références

J Virol. 2000 Sep;74(17):7989-96
pubmed: 10933707
Mol Cell. 1998 Jun;1(7):991-1000
pubmed: 9651582
J Gen Virol. 2003 Dec;84(Pt 12):3263-74
pubmed: 14645908
Genome Biol. 2002 Jun 18;3(7):RESEARCH0034
pubmed: 12184808
J Virol. 2013 Mar;87(5):2430-40
pubmed: 23255794
Virology. 2007 Jun 20;363(1):236-43
pubmed: 17320139
J Psychiatr Res. 2014 Jun;53:62-8
pubmed: 24565447
RNA. 1999 Feb;5(2):195-205
pubmed: 10024172
J Virol. 2005 Jun;79(12):7535-43
pubmed: 15919908
Microbes Infect. 2017 Dec;19(12):587-596
pubmed: 28903072
PLoS Pathog. 2008 Oct;4(10):e1000193
pubmed: 18974865
J Gen Virol. 2010 Dec;91(Pt 12):2907-17
pubmed: 20826615
Elife. 2018 Apr 13;7:
pubmed: 29651984
J Gen Virol. 2012 Jan;93(Pt 1):113-8
pubmed: 21918006
J Virol. 2000 Jul;74(13):6203-6
pubmed: 10846107
J Virol. 2007 Jan;81(2):514-24
pubmed: 17079289
J Histochem Cytochem. 2015 May;63(5):312-28
pubmed: 25604814
J Virol. 2007 Jul;81(13):7011-21
pubmed: 17442719
Annu Rev Biochem. 1991;60:717-55
pubmed: 1883206
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13093-8
pubmed: 18725644
Virology. 1995 Dec 1;214(1):222-8
pubmed: 8525619
Nat Microbiol. 2016 May 27;1(7):16069
pubmed: 27572970
Virology. 2003 Mar 15;307(2):386-95
pubmed: 12667806
J Virol. 1994 Apr;68(4):2425-32
pubmed: 7908060
Apoptosis. 2007 Aug;12(8):1419-32
pubmed: 17468837
J Interferon Cytokine Res. 1998 Sep;18(9):757-66
pubmed: 9781815
EMBO J. 1999 Apr 15;18(8):2273-83
pubmed: 10205180
Cell. 2010 Feb 5;140(3):397-408
pubmed: 20144762
J Virol. 2000 Dec;74(24):11566-73
pubmed: 11090154
Nucleic Acids Res. 1999 Jun 1;27(11):2241-7
pubmed: 10325410
Immunity. 2017 May 16;46(5):875-890.e6
pubmed: 28514692
J Vis Exp. 2014 May 22;(87):null
pubmed: 24894187
PLoS One. 2013 Apr 30;8(4):e63270
pubmed: 23646204
Cell Host Microbe. 2009 May 8;5(5):439-49
pubmed: 19454348
J Gen Virol. 2014 Dec;95(Pt 12):2594-611
pubmed: 25182164
Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14194-9
pubmed: 16963558
Nat Med. 2002 Sep;8(9):950-4
pubmed: 12195436
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7100-5
pubmed: 16627618
Curr Top Microbiol Immunol. 2015;386:73-107
pubmed: 25007846
J Virol. 1988 Aug;62(8):3020-6
pubmed: 2969057
J Gen Virol. 2008 Oct;89(Pt 10):2359-76
pubmed: 18796704
Cell Rep. 2019 Dec 17;29(12):3997-4009.e5
pubmed: 31851929
Structure. 2015 Nov 3;23(11):2001-10
pubmed: 26365801
J Virol. 2013 Apr;87(8):4237-51
pubmed: 23365447
Virology. 2010 Dec 20;408(2):146-58
pubmed: 20934196
EMBO J. 1994 Feb 1;13(3):704-12
pubmed: 8313914
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5598-603
pubmed: 15034168
PLoS One. 2013 Dec 31;8(12):e84673
pubmed: 24391972
J Virol. 2009 Jul;83(13):6849-62
pubmed: 19403682
J Biol Chem. 2007 Mar 9;282(10):7576-81
pubmed: 17204473
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4864-9
pubmed: 9560194
Mol Cell Biol. 2000 Sep;20(17):6259-68
pubmed: 10938102
J Virol Methods. 2011 Apr;173(1):1-6
pubmed: 21185869
Virus Res. 1998 Mar;54(1):59-69
pubmed: 9660072
Virology. 2008 Aug 15;378(1):1-5
pubmed: 18585749
Trends Microbiol. 2018 Jul;26(7):624-636
pubmed: 29373257
J Virol. 2003 Dec;77(24):13257-66
pubmed: 14645582
J Virol. 2014 Apr;88(8):4113-22
pubmed: 24478439
Mol Cell Biol. 1990 May;10(5):2327-34
pubmed: 2183031
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
PLoS Pathog. 2010 Sep 16;6(9):e1001106
pubmed: 20862325
Viruses. 2009 Dec;1(3):1057-72
pubmed: 21994582
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Future Microbiol. 2010 Jan;5(1):23-41
pubmed: 20020828
PLoS Pathog. 2012;8(11):e1003059
pubmed: 23209422
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1954-9
pubmed: 20133840
Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2746-51
pubmed: 11226311
J Virol. 2006 Jul;80(13):6295-304
pubmed: 16775317
Virol J. 2012 Aug 21;9:167
pubmed: 22909121
J Virol. 2007 Sep;81(17):9469-80
pubmed: 17596305
J Immunol. 2019 Jan 15;202(2):382-391
pubmed: 30617120
J Virol. 2010 Jul;84(14):7204-13
pubmed: 20463066
J Virol. 2013 May;87(10):5602-20
pubmed: 23468495
J Biol Chem. 2005 Feb 18;280(7):5571-80
pubmed: 15579900
Viruses. 2012 Dec;4(12):3363-88
pubmed: 23342363
Nat Rev Immunol. 2014 May;14(5):315-28
pubmed: 24762827
J Virol. 2007 Jun;81(11):5995-6006
pubmed: 17376915
J Virol. 1999 Nov;73(11):9679-82
pubmed: 10516084
J Virol. 1999 Mar;73(3):2425-33
pubmed: 9971827

Auteurs

Paula L Monteagudo (PL)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Raquel Muñoz-Moreno (R)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Miguel Fribourg (M)

Department of Medicine Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, New York, USA.

Uma Potla (U)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Ignacio Mena (I)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Nada Marjanovic (N)

Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Boris M Hartmann (BM)

Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Stuart C Sealfon (SC)

Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Adolfo García-Sastre (A)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Department of Medicine Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, New York, USA.
Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Irene Ramos (I)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA irene.ramos-lopez@mssm.edu ana.sesma@mssm.edu.

Ana Fernández-Sesma (A)

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA irene.ramos-lopez@mssm.edu ana.sesma@mssm.edu.
Department of Medicine Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, New York, USA.
The Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH